Brigatinib

Brigatinib
Clinical data
Trade names	Alunbrig, others
Other names	AP26113
AHFS/Drugs.com	Monograph
MedlinePlus	a617016
License data	US DailyMed: Brigatinib;
Pregnancy; category	AU: D;
Routes of; administration	By mouth
ATC code	L01ED04 (WHO) ;
Legal status
Legal status	AU: S4 (Prescription only); CA: ℞-only; UK: POM (Prescription only); US: ℞-only; EU: Rx-only;
Identifiers
	IUPAC name 5-Chloro-2-N-{4-[4-(dimethylamino)piperidin-1-yl]-2-methoxyphenyl}-4-N-[2-(dimethylphosphoryl)phenyl]pyrimidine-2,4-diamine;
CAS Number	1197953-54-0;
PubChem CID	68165256;
IUPHAR/BPS	7741;
ChemSpider	34982928;
UNII	HYW8DB273J;
KEGG	D10866;
PDB ligand	6GY (PDBe, RCSB PDB);
CompTox Dashboard (EPA)	DTXSID501027929 ;
Chemical and physical data
Formula	C29H39ClN7O2P
Molar mass	584.10 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES COc1cc(ccc1Nc1ncc(Cl)c(Nc2ccccc2P(C)(C)=O)n1)N1CCC(CC1)N1CCN(C)CC1;
	InChI InChI=1S/C29H39ClN7O2P/c1-35-15-17-37(18-16-35)21-11-13-36(14-12-21)22-9-10-24(26(19-22)39-2)33-29-31-20-23(30)28(34-29)32-25-7-5-6-8-27(25)40(3,4)38/h5-10,19-21H,11-18H2,1-4H3,(H2,31,32,33,34); Key:AILRADAXUVEEIR-UHFFFAOYSA-N;

Brigatinib, sold under the brand name Alunbrig among others, is a small-molecule targeted cancer therapy being developed by Ariad Pharmaceuticals, Inc. Brigatinib acts as both an anaplastic lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR) inhibitor.

Brigatinib could overcome resistance to osimertinib conferred by the EGFR C797S mutation if it is combined with an anti-EGFR antibody such as cetuximab or panitumumab.